<DOC>
	<DOCNO>NCT00691587</DOCNO>
	<brief_summary>Pseudomonas aeruginosa opportunistic pathogen rarely cause disease healthy people , significant problem critically ill immunocompromised individual . Experts estimate great 100,000 patient United States , Europe Japan Pseudomonas pneumonia occurs . Patients Pseudomonas pneumonia currently represent 20 % patient hospital get Pseudomonas infection .</brief_summary>
	<brief_title>Pilot Trial KB001 Mechanically-Ventilated Patients Colonized With Pseudomonas Aeruginosa</brief_title>
	<detailed_description>This trial evaluate KB001 patient intensive care set receive ventilator therapy Pseudomonas infection . They receive either placebo , one two dose level KB001 , Humaneeredâ„¢ , high-affinity antibody fragment KaloBios develop treatment Pseudomonas aeruginosa ( Pa ) infection . This trial evaluate ability KB001 protect host epithelium immune cell , evaluate reduction pulmonary Pa burden .</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Ventilator-Associated</mesh_term>
	<mesh_term>Pseudomonas Infections</mesh_term>
	<criteria>Provision write informed consent obtain patient patient 's surrogate unconscious alter sensorium Age &gt; 18 year On mechanical ventilation expect remain mechanically ventilate least 3 day Documented pulmonary Pa colonization Patients know chronic pulmonary infection Pa ( i.e. , patient cystic fibrosis ) Patient currently diagnose Pa VAP Change systemic antibiotic therapy active Gram negative bacteria within 72 hour Use investigational medication within 4 week prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>mechanical ventilation</keyword>
	<keyword>mechanically ventilate</keyword>
	<keyword>Pseudomonas aeruginosa</keyword>
	<keyword>ventilator associate pneumonia</keyword>
</DOC>